



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **Anthony Hunter, M.D.**

Committee: **Oncologic Drugs Advisory Committee**

Meeting Date: **March 14, 2024**

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On March 14, 2024, the Committee will discuss new drug application (NDA) 217779 for imetelstat for injection, submitted by Geron Corporation. The proposed indication for this product is for the treatment of transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
Contracts/grants	Employer’s research funded by Novartis, a competing firm	\$0 - \$50,000 per year to Emory University
Contracts/grants	Employer’s research funded by Syntrix Biosystems, a competing firm	\$0 - \$50,000 per year to Emory University \$0 - \$5,000 per year to Dr. Hunter

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/_____
Signature

Date **2/26/2024**